JaxBio Technologies

JaxBio Technologies Overview

JaxBio aims to change the way cancer is diagnosed and managed, with a simple and sensitive blood test. This test will enable early detection, monitoring of disease status, and predicting response to therapy. The company has developed an ultra-sensitive method to detect genetic and epigenetic profiles in cell-free DNA, that occur during cancer initiation and progression. It extracts cell-free DNA from a blood sample and fluorescently label markers utilizing a proprietary process. The DNA is hybridized onto a custom chip, and each cancer type presents a unique pixel pattern signature that may be used for classifying the type and stage of the disease. JaxBio is currently focused on developing its first diagnostic tests for lung cancer and hematological malignancies.

Cumulative Funding Raised Over Time ($)

Latest News

Jul 17, 2024 · www.finsmes.com

growth-positive

JaxBio Technologies Secures €2.5M Grant from European Innovation Council Accelerator

JaxBio Technologies, a medical diagnostics company based in Netanya, Israel, has secured a €2.5M grant from the European Innovation Council (EIC) Accelerator. The grant includes the option for future blended financing, with a potential additional €9.1M from the EU and a matching €9.1M from other investors. The company plans to use the funds to expand clinical programs and develop its diagnostics platform to create a blood test for making lung cancer detection and management simpler, quicker, and highly accurate.

InvestmentExpand

Jan 3, 2023 · www.genomeweb.com

growth-positive

Israeli Startup JaxBio Snags €8.5M EU Grant to Support Creation of Array-Based Cancer Tests

JaxBio Technologies, an Israeli company, has received an €8.5 million EU Horizon Europe grant to support the development of a new array-based platform for diagnosing hematological malignancies. The project, called Sanguine, aims to develop a liquid biopsy-based test that can classify a set of hematological malignancies by detecting epigenetic markers in peripheral blood cells and cell-free DNA. The test will use a custom microarray called the HemaChip. The funding will pave the way for the eventual deployment of the test in clinical settings. JaxBios technology is a cost-effective and scalable alternative to sequencing and PCR. The company is also working on a project called Base6 to develop a custom microarray targeted to 5-hydroxymethylcytosine. JaxBio is planning a series A round in the near future.

InvestmentPartnersExpand

Funding

Team Members

4

Employees: 11-50

Web & Social Links

Locations

Sderot Giborei Israel 7, Netanya, Israel

Photos & Videos

No files yet

JaxBio Technologies Internal

Recent Updates

No update log entries.

Note: Free-text notes visible in the original Finder "Internal" tab are not present in the imported profile data. Only the update audit log is available.

Admin Info